In a subsequent update on RA, several clinical variables related to specific drugs and host characteristics were analyzed to guide the choice towards anti-TNF b-DMARDs, non-anti-TNF b-DMARDs, or tS-DMARDs, thus allowing for personalized therapy, taking into account the results of the literature when the chosen variables predominated over the economic aspect [5]. The gene discussed is TNF; the disease is rheumatoid arthritis.